Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody

Shiwen Peng; Louise Ferrall; Stephanie Gaillard; Chenguang Wang; Wei-Yu Chi; Chuan-Hsiang Huang; Richard B. S. Roden; T.-C. Wu; Yung-Nien Chang; Chien-Fu Hung

doi:10.1128/mBio.03224-20

mBio (Feb 2021)

Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody

Shiwen Peng,
Louise Ferrall,
Stephanie Gaillard,
Chenguang Wang,
Wei-Yu Chi,
Chuan-Hsiang Huang,
Richard B. S. Roden,
T.-C. Wu,
Yung-Nien Chang,
Chien-Fu Hung

Affiliations

Shiwen Peng: Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA
Louise Ferrall: Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA
Stephanie Gaillard: Department of Oncology, The Johns Hopkins University, Baltimore, Maryland, USA
Chenguang Wang: Department of Oncology Biostatistics, The Johns Hopkins University, Baltimore, Maryland, USA
Wei-Yu Chi: Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA
Chuan-Hsiang Huang: Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA
Richard B. S. Roden: ORCiD; Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA
T.-C. Wu: ORCiD; Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA
Yung-Nien Chang: Papivax Biotech Inc., Taipei, Taiwan, Republic of China
Chien-Fu Hung: ORCiD; Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, USA

DOI: https://doi.org/10.1128/mBio.03224-20
Journal volume & issue: Vol. 12, no. 1

Abstract

Read online

Persistent expression of high-risk human papillomavirus (HPV) E6 and E7 is an obligate driver for several human malignancies, including cervical cancer, wherein HPV16 and HPV18 are the most common types. PD-1 antibody immunotherapy helps a subset of cervical cancer patients, and its efficacy might be improved by combination with active vaccination against E6 and/or E7.

Published in mBio

ISSN: 2161-2129 (Print); 2150-7511 (Online)
Publisher: American Society for Microbiology
Country of publisher: United States
LCC subjects: Science: Microbiology
Website: https://journals.asm.org/journal/mbio

About the journal